Roquefort Therapeutics (LON:ROQ) Stock Price Up 10.2% – Here’s Why

Roquefort Therapeutics plc (LON:ROQ) shares rose 10.2% during trading on Thursday . The company traded as high as GBX 5.50 ($0.07) and last traded at GBX 4.47 ($0.06). Approximately 1,300,436 shares were traded during mid-day trading, an increase of 117% from the average daily volume of 599,877 shares. The stock had previously closed at GBX 4.05 ($0.05).

Roquefort Therapeutics Price Performance

The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37. The firm has a market cap of £5.37 million, a price-to-earnings ratio of -416.00 and a beta of 0.05. The company has a 50 day moving average of GBX 4.32 and a 200 day moving average of GBX 4.13.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action.